TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03566901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EO System
Description: The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
Study: NCT01141257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiocal® (PRS-050-PEG40)
Description: Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
Study: NCT03169465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic approach
Description: excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
Study: NCT02014363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETS6103 (low dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETS6103 (high dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Study: NCT02864849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT02102776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pterygium excision
Description: Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
Study: NCT03392623

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: colorimetry measurement
Description: Measurement of erythema and luminosity through a colorimeter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sunscreen
Description: topical administration in melasma lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: topical administration in melasma lesions
Study: NCT01081743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of the social worker
Description: Systematic home visits and regular follow-ups by phone from a social worker
Study: NCT02272218

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric lap band surgery
Description: The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
Study: NCT00002961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
Study: NCT02864849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Study: NCT01636726

Intervention type: DRUG
Intervention: Inhaled LABA use
Description: LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009

Intervention type: DRUG
Intervention: Inhaled LABA use
Description: LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
Study: NCT00488267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)
Description: Transdermal patch applied to the knee for 12 hours daily.
Study: NCT00002961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy.
Study: NCT00488267

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matrix/CHADD Patch
Description: Transdermal patch applied to the knee for 12 hours daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen matrix/placebo CHADD Patch
Description: Transdermal knee applied to the knee for 12 hours daily.
Study: NCT01966679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02481011

Intervention type: DRUG
Intervention: antithrombotic drugs
Study: NCT04842942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TOETVA
Description: Transoral Endoscopic Thyroidectomy Vestibular Approach
Study: NCT01466972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Oral, 800mg tablet daily per cycle
Study: NCT03245372

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed therapy
Description: The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
Study: NCT03338699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShangRing
Description: Topical anesthesia based, no-flip ShangRing circumcision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mogen clamp
Description: Mogen clamp circumcision
Study: NCT03102164

Intervention type: PROCEDURE
Intervention: cardiac rehabilitation
Description: The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
Study: NCT01230827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 148 (Golimumab)
Description: Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
Study: NCT01116726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced community services
Description: Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced community services
Description: Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
Study: NCT00889031

Intervention type: OTHER
Intervention: No Intervention
Description: Patients with Chronic Lymphocytic Leukemia (CLL)
Study: NCT02545504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
Study: NCT02950844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel mapping algorithm
Description: Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF.
Study: NCT02576808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger extract
Description: Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
Study: NCT04046250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TK-112690
Description: TK112690 treatment pre-methotrexate treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TK-112690
Description: Placebo
Study: NCT03834220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1347
Description: Debio 1347 oral tablets.
Study: NCT01031862

Intervention type: OTHER
Group type: OTHER
Intervention: 3H-Cholesterol
Description: A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
Study: NCT01140646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine disulfate p-toluene-sulfonate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02868658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal swab
Study: NCT03395002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder
Description: Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg Inhalation Powder
Description: Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
Study: NCT03887858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration under fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
Study: NCT01553643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese Herb Huang-Chi-Wu-Wu-Tang
Description: Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: at a rate of 3g two times per day
Study: NCT01735370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Tablets USP 500mg
Description: 500 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac Tablets USP 500 mg
Description: 500 mg tablet once a day
Study: NCT01264419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk Road Embolic Protection System
Description: System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
Study: NCT00888485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral interventional program
Description: Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral interventional program
Description: Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
Study: NCT02478255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129-Xenon gas
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
Study: NCT00208351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collared Stem - Non-Polished/Blasted Finished
Description: A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collared Stem - Polished Finished
Description: A collared polished finished cementless femoral component for use in total hip replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collarless Stem - Non-Polished/Blasted Finished
Description: A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultima LX Collarless Stem - Polished finished
Description: A collarless polished finished cementless femoral component for use in total hip replacement.
Study: NCT02561559

Intervention type: RADIATION
Intervention: Lung metastasis from soft-tissue sarcoma
Description: Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
Study: NCT03753139

Intervention type: DEVICE
Intervention: Heart rhythm monitoring with portable device
Description: The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.

Intervention type: DEVICE
Intervention: Heart rhythm monitoring with portable device
Description: The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~1. Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~2. Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~3. Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~4. Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel.
Study: NCT01140646

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT04160494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT (6920 ng/mL via convection-enhanced delivery)
Description: dual-specific mAB
Study: NCT03975569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic vaginal gel
Description: Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10\^9-10\^10 colony forming units of lactobacilli.
Study: NCT01942070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durable polymer everolimus-eluting metallic stent
Study: NCT03883087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: 40 mg tablet, taken orally once every other day of a 28-day cycle
Study: NCT01392287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8
Study: NCT00613093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temodar and O6-Benzylguanine (BG)
Description: Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temodar and O6-Benzylguanine (BG)
Description: Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle.
Study: NCT00852241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restalyne
Description: one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.